Document is current
Any future updates will be listed below
-
Authors
De Man, Ruben https://orcid.org/0000-0001-5468-0281
McDonough, John E.
Adams, Taylor S. https://orcid.org/0000-0003-4280-9070
Nikola, Fadi
Rangel, Reina
Anderson, Sabina
Manning, Edward P. https://orcid.org/0000-0002-4430-8168
Cala Garcia, Juan https://orcid.org/0000-0002-2571-1373
Moss, Benjamin
Waich, Alan
Poli, Fernando
Cardenas, Rafael
Coarfa, Cristian https://orcid.org/0000-0002-4183-4939
Song, Qi https://orcid.org/0000-0001-5420-4031
Bar-Joseph, Ziv https://orcid.org/0000-0003-3430-6051
Vanaudenaerde, Bart M. https://orcid.org/0000-0001-6435-6901
Wuyts, Wim A.
Niklason, Laura
Raredon, Micha Sam B. https://orcid.org/0000-0003-1441-6122
Yan, Xiting https://orcid.org/0000-0001-8688-9004
Rosas, Ivan O.
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL127349)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL141852)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U01HL145567)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (UH2HL123886)
- License Information
-
More Information
Article History
Received: 21 November 2024
Accepted: 16 January 2026
First Online: 22 January 2026
Competing interests
: N.K. served as a consultant to Boehringer Ingelheim, Nuvectis, Baobab, GlaxoSmithKline, Pliant, Samumed, Three Lake Partners, Astra Zeneca, Augmanity, CSL Behring, Galapagos, Fibrogen, and Thyron over the last 3 years, reports Equity in Pliant, and grants from Astra Zeneca and BMS. L.N. is the founder, President, and CEO of Humacyte Global Inc, a publicly traded regenerative medicine company. MSBR holds stock in and serves as a consultant for Humacyte Inc. The remaining authors declare no conflicts of interest.
